2006
Epirubicin Glucuronidation and UGT2B7 Developmental Expression
Zaya M, Hines R, Stevens J. Epirubicin Glucuronidation and UGT2B7 Developmental Expression. Drug Metabolism And Disposition 2006, 34: 2097-2101. PMID: 16985101, DOI: 10.1124/dmd.106.011387.Peer-Reviewed Original ResearchConceptsPediatric age categoriesPediatric age groupAge categoriesAge groupsLiver microsomesChildhood malignant diseaseMetabolism of epirubicinUse of epirubicinTreatment of adultsYears of ageMonths of ageAge-related changesPediatric patientsAdult age categoriesPostnatal ageCardiac toxicityMalignant diseaseUGT2B7 activityNeonatal samplesPreclinical evaluationUGT2B7 expressionGlucuronidation activityAdult groupGlucuronidationEquivalent dosesThe Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines
Krueger S, VanDyke J, Williams D, Hines R. The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines. Drug Metabolism Reviews 2006, 38: 139-147. PMID: 16684653, DOI: 10.1080/03602530600569919.Peer-Reviewed Original ResearchConceptsMetabolism of tamoxifenBreast cancer therapyHuman liver microsomesFlavin-Containing MonooxygenaseMetabolic activation pathwayEndometrial cancerTamoxifen metabolismN-oxide productionLiver microsomesTamoxifenMetabolic activationDNA adductionCancer therapyActivation pathwayCytochrome P450Detoxication pathwayN-oxygenationRiskMetabolismLow levelsPathwayChemopreventionNeoplasiaTherapyCancer
1980
EVIDENCE FOR INHIBITORY COMPLEXES FORMED WITH CYTOCHROME P-450 AND A METABOLITE OF 1,1-DISUBSTITUTED HYDRAZINES11Supported by NIH Grant T32/GM07072 and Robert A. Welch Foundation Grant I-616.
Hines R, Prough R. EVIDENCE FOR INHIBITORY COMPLEXES FORMED WITH CYTOCHROME P-450 AND A METABOLITE OF 1,1-DISUBSTITUTED HYDRAZINES11Supported by NIH Grant T32/GM07072 and Robert A. Welch Foundation Grant I-616. 1980, 1215-1218. DOI: 10.1016/b978-0-12-187702-6.50117-1.Peer-Reviewed Original Research